Global Granulomatous Lobular Mastitis Treatment Market, By Type (Idiopathic granulomatous mastitis, granulomatous mastitis), By Diagnosis (Ultrasound, mammography, and magnetic resonance imaging), By Treatment (Surgical excision, Abscess Drainage, Use of corticosteroids, Antibiotics) – Industry Trends and Forecast to 2029
Granulomatous Lobular Mastitis Treatment Market Analysis and Size
The global granulomatous lobular mastitis treatment market is expected to witness significant growth during the forecast period. G.M. is a rare differential diagnosis with an estimated prevalence of 2.4 per 100,000 women and 0.37 percent in the U.S. Both the practitioner and the patient who frequently has to endure a protracted disease course with a major impact on quality of life still find it difficult to diagnose and treat a patient with G.M. Before the diagnosis of G.M. can be considered, many causes of mastitis, and most especially cancer, typically need to be ruled out. The disease has greatly impacted the population and in return in the market.
Data Bridge Market Research analyses a growth rate in the global granulomatous lobular mastitis treatment market in the forecast period 2022-2029. The expected CAGR of global granulomatous lobular mastitis treatment market is tend to be around 3.0% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Granulomatous lobular mastitis is a long-lasting inflammatory condition that only affects the mammary gland's lobules and does not cause caseous necrosis. IGM appears to be a state of "benign disease and malignant invasion" based on its clinical presentations; it is locally invasive and has a recurrence rate as high as 50%.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Idiopathic granulomatous mastitis, granulomatous mastitis), By Diagnosis (Ultrasound, mammography, and magnetic resonance imaging), By Treatment (Surgical excision, Abscess Drainage, Use of corticosteroids, Antibiotics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GlaxoSmithKline plc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Boehringer Ingelheim International Gmbh (Germany), Sanofi (France), Astrazeneca (U.K.), AbbVie Inc. (U.S.), Abbott (U.S.), Bayer AG (Germany), Johnson & Johnson Services, Inc. (U.S.), Allergan (Ireland), Cipla Inc. (U.S.), Bristol-Myers Squibb Company (U.S.) and Mylan N.V. (U.S.)
|
|
Market Opportunities
|
|
Global Granulomatous Lobular Mastitis Treatment Market Dynamics
Drivers
- Incidence of granulomatous lobular mastitis
Since granulomatous mastitis was first described as a benign disease entity in 1972, hundreds of cases have been reported globally. Nevertheless, G.M. is a rare differential diagnosis with an estimated incidence of 2.4 per 100,000 women and 0.37% in the U.S.
- Increasing Investment For Healthcare Infrastructure
The expanding healthcare expenditure which aids in the betterment of its infrastructure is also another driving force in this market. Additionally, several government organizations are aiming to uplift the healthcare infrastructure by more funding, which will further influence the market dynamics.
Opportunities
- Technological Advancements
The rising technological advancement in treatment methods is expected to create new market opportunities. For instance, surgical excisions are being performed recently and it shows a higher complete remission rate (90.6%) than those with oral steroids single therapy (71.8%). Also, the growth is boosted by rising reimbursement and insurance policies and the emerging new markets
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global granulomatous lobular mastitis treatment market over a forecast period.
- High Cost
The high cost of these treatments can hinder the growth of the global granulomatous lobular mastitis treatment market even though the prevalence of diseases is high.
This global granulomatous lobular mastitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global granulomatous lobular mastitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Granulomatous Lobular Mastitis Treatment Market Scope
The global granulomatous lobular mastitis treatment market is segmented on the basis of type, diagnosis and treatment. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Idiopathic granulomatous mastitis
- Granulomatous mastitis
Diagnosis
- Ultrasound
- Mammography
- Magnetic resonance imaging
Treatment
- Surgical excision
- Abscess Drainage
- Use of corticosteroids
- Antibiotics
Granulomatous Lobular Mastitis Treatment Market Regional Analysis/Insights
The global granulomatous lobular mastitis treatment market is analysed and market size insights and trends are provided by type, diagnosis and treatment as referenced above.
The major countries covered in the global granulomatous lobular mastitis treatment market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is the dominating region in the global granulomatous lobular mastitis treatment market due to growing rate of surgeries and increasing number of patients with granulomatous lobular mastitis
Meanwhile, the Asia-Pacific region has shown significant growth in the global granulomatous lobular mastitis treatment market due to rising investments in the medical treatment sector.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Granulomatous Lobular Mastitis Treatment Market Share Analysis
The global granulomatous lobular mastitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global granulomatous lobular mastitis treatment market
Key players operating in the global granulomatous lobular mastitis treatment market include:
- GlaxoSmithKline plc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Novartis AG (Switzerland)
- Boehringer Ingelheim International Gmbh (Germany)
- Sanofi (France)
- Astrazeneca (U.K.)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
- Bayer AG (Germany)
- Johnson & Johnson Services, Inc. (U.S.)
- Allergan (Ireland)
- Cipla Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Mylan N.V. (U.S.)
SKU-